Drug Discovery and Development to focus on pharmaceutical trends

NewsGuard 100/100 Score

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City.

Dr. Seymour will join other industry panelists in the “Drug Discovery and Development” session to discuss early to mid-stage financing and pharmaceutical alliance challenges and trends. The panelists and participants include pharmaceutical and biotech decision makers and executives, investors, government and regulatory agency representatives from a number of countries.

This is a unique, by invitation conference, designed to bring together key stakeholders from pharmaceutical, finance and investment, business strategy, as well as governmental science and regulatory segments, according to Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities.

“This is an important opportunity to network with significant decision-makers in our industry,” said Dr. Seymour.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery